UA75402C2 - Use of pyrazoline derivative for the preparation of medicament for prevention or treatment of proliferative cellular diseases - Google Patents

Use of pyrazoline derivative for the preparation of medicament for prevention or treatment of proliferative cellular diseases Download PDF

Info

Publication number: UA75402C2
Authority: UA; Ukraine
Prior art keywords: trifluoromethyl; pyrazole; dihydro; methylsulfonylphenyl; methyl
Prior art date: 2001-04-06

Application number

UA2003119998A

Other languages

English (en)

Ukrainian (uk)

Inventor

Maria Rosa Cuberes-Altisent

Juana Maria Berrocal-Romero

Maria Montesar Contihoch-Yobet

Original Assignee

Del Dr Estebe S A Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2002-03-21

Publication date

2006-04-17

2002-03-21 Application filed by Del Dr Estebe S A Lab filed Critical Del Dr Estebe S A Lab

2006-04-17 Publication of UA75402C2 publication Critical patent/UA75402C2/uk

Links

230000002265 prevention Effects 0.000 title claims abstract description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 11
201000010099 disease Diseases 0.000 title claims abstract description 9
230000002062 proliferating effect Effects 0.000 title claims abstract description 8
150000003219 pyrazolines Chemical class 0.000 title claims abstract description 5
238000002360 preparation method Methods 0.000 title claims description 9
239000003814 drug Substances 0.000 title description 9
230000001413 cellular effect Effects 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 31
-1 acetylaminosulfonyl Chemical group 0.000 claims abstract description 27
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 25
229910052731 fluorine Inorganic materials 0.000 claims abstract description 22
239000011737 fluorine Substances 0.000 claims abstract description 20
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 18
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 16
239000000460 chlorine Substances 0.000 claims abstract description 16
229910052801 chlorine Inorganic materials 0.000 claims abstract description 16
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims abstract description 16
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract description 14
239000001257 hydrogen Substances 0.000 claims abstract description 14
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 11
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 9
125000001424 substituent group Chemical group 0.000 claims abstract description 8
125000005599 alkyl carboxylate group Chemical group 0.000 claims abstract description 3
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims abstract description 3
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 43
102000010907 Cyclooxygenase 2 Human genes 0.000 claims description 31
108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 31
238000000034 method Methods 0.000 claims description 22
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 20
230000014509 gene expression Effects 0.000 claims description 20
108090000623 proteins and genes Proteins 0.000 claims description 19
230000008569 process Effects 0.000 claims description 17
230000005764 inhibitory process Effects 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
206010006895 Cachexia Diseases 0.000 claims description 10
230000015572 biosynthetic process Effects 0.000 claims description 10
238000003786 synthesis reaction Methods 0.000 claims description 10
208000008636 Neoplastic Processes Diseases 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 6
229940126601 medicinal product Drugs 0.000 claims description 6
230000005747 tumor angiogenesis Effects 0.000 claims description 5
150000003857 carboxamides Chemical class 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
102000003390 tumor necrosis factor Human genes 0.000 claims 6
DXANXCBCSPZANW-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C=CC(F)=CC=2)N=C(C(F)(F)F)C1 DXANXCBCSPZANW-UHFFFAOYSA-N 0.000 claims 2
WYTGCYYFONATBA-UHFFFAOYSA-N 2-(2,4-dimethylphenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound CC1=CC(C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)CC(C(F)(F)F)=N1 WYTGCYYFONATBA-UHFFFAOYSA-N 0.000 claims 1
DMMVWGZOGYNMGY-UHFFFAOYSA-N 2-(2-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C(=CC=CC=2)F)N=C(C(F)(F)F)C1 DMMVWGZOGYNMGY-UHFFFAOYSA-N 0.000 claims 1
SWAUQQYFPQVQSJ-UHFFFAOYSA-N 2-(3-methylphenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound CC1=CC=CC(N2C(CC(=N2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 SWAUQQYFPQVQSJ-UHFFFAOYSA-N 0.000 claims 1
RTHYHPLQWLNMPZ-UHFFFAOYSA-N 2-(4-chloro-2-methylphenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound CC1=CC(Cl)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)CC(C(F)(F)F)=N1 RTHYHPLQWLNMPZ-UHFFFAOYSA-N 0.000 claims 1
BQMJBDAPQSEBHC-UHFFFAOYSA-N 2-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)CC(C(F)(F)F)=N1 BQMJBDAPQSEBHC-UHFFFAOYSA-N 0.000 claims 1
ICDOEQFGMOCZMV-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-phenyl-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC=CC=2)CC(C(F)(F)F)=N1 ICDOEQFGMOCZMV-UHFFFAOYSA-N 0.000 claims 1
WGTRCKXLJLADDX-UHFFFAOYSA-N 3-(4-fluorophenyl)-5-methyl-2-(4-methylsulfonylphenyl)-3,4-dihydropyrazole Chemical compound C1C(C)=NN(C=2C=CC(=CC=2)S(C)(=O)=O)C1C1=CC=C(F)C=C1 WGTRCKXLJLADDX-UHFFFAOYSA-N 0.000 claims 1
HFHHSMJIOSROMS-UHFFFAOYSA-N 3-(4-methylphenyl)-2-(4-methylsulfonylphenyl)-3,4-dihydropyrazole-5-carbonitrile Chemical compound C1=CC(C)=CC=C1C1N(C=2C=CC(=CC=2)S(C)(=O)=O)N=C(C#N)C1 HFHHSMJIOSROMS-UHFFFAOYSA-N 0.000 claims 1
SALWHXXPZFQWIF-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-2-phenyl-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C=CC=CC=2)N=C(C(F)(F)F)C1 SALWHXXPZFQWIF-UHFFFAOYSA-N 0.000 claims 1
QDJRZKJPHCZNDT-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-2-[2-(trifluoromethyl)phenyl]-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C(=CC=CC=2)C(F)(F)F)N=C(C(F)(F)F)C1 QDJRZKJPHCZNDT-UHFFFAOYSA-N 0.000 claims 1
VKKYVYAAEHCIQR-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-3-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1N(C=2C=CC(F)=CC=2)N=C(C(F)(F)F)C1 VKKYVYAAEHCIQR-UHFFFAOYSA-N 0.000 claims 1
VMRBITBSIDDKSD-UHFFFAOYSA-N 5-methyl-3-(4-methylsulfonylphenyl)-2-phenyl-3,4-dihydropyrazole Chemical compound C1C(C)=NN(C=2C=CC=CC=2)C1C1=CC=C(S(C)(=O)=O)C=C1 VMRBITBSIDDKSD-UHFFFAOYSA-N 0.000 claims 1
OMRRUNXAWXNVFW-UHFFFAOYSA-N fluoridochlorine Chemical compound ClF OMRRUNXAWXNVFW-UHFFFAOYSA-N 0.000 claims 1
230000009826 neoplastic cell growth Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract 1
125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 32
230000000694 effects Effects 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
239000000243 solution Substances 0.000 description 14
239000000047 product Substances 0.000 description 9
230000033115 angiogenesis Effects 0.000 description 8
206010009944 Colon cancer Diseases 0.000 description 7
108010074860 Factor Xa Proteins 0.000 description 7
108060001084 Luciferase Proteins 0.000 description 7
208000015634 Rectal Neoplasms Diseases 0.000 description 7
239000000203 mixture Substances 0.000 description 7
206010038038 rectal cancer Diseases 0.000 description 7
201000001275 rectum cancer Diseases 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
206010006187 Breast cancer Diseases 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 6
230000006907 apoptotic process Effects 0.000 description 6
208000029742 colonic neoplasm Diseases 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
230000006698 induction Effects 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
QOCDZDDDUCWJFM-DUXPYHPUSA-N (e)-4-(2,4-difluorophenyl)-1,1,1-trifluorobut-3-en-2-one Chemical compound FC1=CC=C(\C=C\C(=O)C(F)(F)F)C(F)=C1 QOCDZDDDUCWJFM-DUXPYHPUSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
ZZMJXWXXMAAPLI-UHFFFAOYSA-N 4-[3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 ZZMJXWXXMAAPLI-UHFFFAOYSA-N 0.000 description 4
101150071146 COX2 gene Proteins 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000001629 suppression Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000001772 anti-angiogenic effect Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
230000035772 mutation Effects 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
229920000392 Zymosan Polymers 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001023 pro-angiogenic effect Effects 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
125000003831 tetrazolyl group Chemical group 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
NYYLZXREFNYPKB-UHFFFAOYSA-N 1-[ethoxy(methyl)phosphoryl]oxyethane Chemical compound CCOP(C)(=O)OCC NYYLZXREFNYPKB-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
ZZMJXWXXMAAPLI-AWEZNQCLSA-N 4-[(3s)-3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1[C@H](C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 ZZMJXWXXMAAPLI-AWEZNQCLSA-N 0.000 description 1
IKEURONJLPUALY-UHFFFAOYSA-N 4-hydrazinylbenzenesulfonamide;hydron;chloride Chemical compound [Cl-].NS(=O)(=O)C1=CC=C(N[NH3+])C=C1 IKEURONJLPUALY-UHFFFAOYSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
208000004804 Adenomatous Polyps Diseases 0.000 description 1
108010055400 Aspartate kinase Proteins 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010058643 Fungal Proteins Proteins 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010013563 Lipoprotein Lipase Proteins 0.000 description 1
102100022119 Lipoprotein lipase Human genes 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
206010027417 Metabolic acidosis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
101800001776 Nuclear inclusion protein B Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
125000000783 acetimidoyl group Chemical group C(C)(=N)* 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
210000004712 air sac Anatomy 0.000 description 1
238000005882 aldol condensation reaction Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
229940124443 chemopreventive agent Drugs 0.000 description 1
239000012627 chemopreventive agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000011549 crystallization solution Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
231100000024 genotoxic Toxicity 0.000 description 1
230000001738 genotoxic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000000752 ionisation method Methods 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
230000016833 positive regulation of signal transduction Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UA2003119998A 2001-04-06 2002-03-21 Use of pyrazoline derivative for the preparation of medicament for prevention or treatment of proliferative cellular diseases UA75402C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200100818A ES2174757B1 (es)	2001-04-06	2001-04-06	Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
PCT/ES2002/000137 WO2002080909A1 (fr)	2001-04-06	2002-03-21	Utilisation de derives de pyrazolines dans l'elaboration d'un medicament pour la prevention et/ou le traitement de maladies proliferatives cellulaires

Publications (1)

Publication Number	Publication Date
UA75402C2 true UA75402C2 (en)	2006-04-17

Family

ID=8497370

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003119998A UA75402C2 (en)	2001-04-06	2002-03-21	Use of pyrazoline derivative for the preparation of medicament for prevention or treatment of proliferative cellular diseases

Country Status (26)

Country	Link
US (1)	US20040034082A1 (fr)
EP (2)	EP1516621A3 (fr)
JP (1)	JP4451599B2 (fr)
KR (1)	KR20040025912A (fr)
CN (2)	CN1698602A (fr)
AT (1)	ATE326966T1 (fr)
AU (1)	AU2002246152B2 (fr)
BR (1)	BR0208805A (fr)
CA (1)	CA2442974C (fr)
CY (1)	CY1105523T1 (fr)
DE (1)	DE60211681T2 (fr)
DK (1)	DK1384477T3 (fr)
ES (2)	ES2174757B1 (fr)
HU (1)	HUP0400918A3 (fr)
IL (1)	IL158269A0 (fr)
IS (1)	IS6973A (fr)
MA (1)	MA27019A1 (fr)
MX (1)	MXPA03009124A (fr)
NO (1)	NO20034470L (fr)
NZ (1)	NZ529304A (fr)
PL (1)	PL365220A1 (fr)
PT (1)	PT1384477E (fr)
RU (1)	RU2305545C2 (fr)
UA (1)	UA75402C2 (fr)
WO (1)	WO2002080909A1 (fr)
ZA (1)	ZA200308626B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20070044799A (ko) *	2004-02-16	2007-04-30	라보라토리오스 델 드라. 에스테브.에스.에이.	암 치료에 유용한 피라졸린 유도체
ES2238923B1 (es) *	2004-02-16	2006-11-01	Laboratorios Del Dr. Esteve, S.A.	Nuevos derivados pirazolinicos sustituidos.
BRPI0507790A (pt) *	2004-02-17	2007-07-17	Esteve Labor Dr	composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1637522A1 (fr) *	2004-09-16	2006-03-22	Laboratorios Del Dr. Esteve, S.A.	Composés de pyrazolines substituées pour réduire des triglycerides dans le sang
US7998996B2 (en)	2004-02-17	2011-08-16	Laboratorios Del Dr. Esteve S.A.	Substituted pyrazoline compounds for reducing triglycerides in blood
EP1743890A1 (fr)	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments.
EP1849776A1 (fr) *	2006-04-26	2007-10-31	Laboratorios Del Dr. Esteve, S.A.	Dérivés de la pyrazoline azépane- ou azocane-substituées, leur préparation et utilisation comme médicaments
EP1749525A1 (fr) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Combination de pyrazoline substitués et de médicaments contre la dépendance
WO2007009693A1 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr.Esteve, S.A	Combinaison d'un compose pyrazolinique substitue et medicament utilise pour des troubles en lien avec les aliments
ES2326725B1 (es) *	2005-07-15	2010-05-11	Laboratorios Del Dr. Esteve, S.A.	Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
WO2007009700A2 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique
EP1743892A1 (fr) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Composés pyrazoline substitués, leur préparation et utilisation comme médicaments
EP1749526A1 (fr) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques
ES2326724B1 (es) *	2005-07-15	2010-05-11	Laboratorios Del Dr. Esteve, S.A.	Nuevas formulaciones de compuestos de pirazolina sustituidos.
WO2007009702A2 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments
US7897589B2 (en)	2005-07-15	2011-03-01	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009699A2 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A	Utilisation de composes pyrazoliniques substitues et de leurs derives contre des affections associees au systeme des cannabinoides
ES2327379B1 (es) *	2005-07-15	2010-05-28	Laboratorios Del Dr. Esteve, S.A.	Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
EP1746090A1 (fr) *	2005-07-15	2007-01-24	Laboratorios del Dr. Esteve S.A.	Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
WO2007009701A2 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Utilisation de composes pyrazoliniques substitues pour traiter des facteurs de risque cardiovasculaires imputables a des troubles du metabolisme ou de l'alimentation
EP1749527A1 (fr) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Utilisation des derivés du pyrazole pour le traitement du syndrome métabolique
EP1743643A1 (fr) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Nouvelles formulations de composés à base de pyrazoline
EP1743636A1 (fr) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Combinaison d'une pyrazoline substituée avec un agent utilisé contre les dérangements alimentaires
WO2007009691A2 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Combinaison de substances active s
EP1743642A1 (fr) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Utilisation de composés à base de pyrazoline pour le traitement des maladies associées avec le système cannabinoïde
EP1743637A1 (fr) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Utilisation des derivés du pyrazole seuls ou en combinaison pour le traitement du syndrome métabolique
EP1743639A1 (fr) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Utilisation des derivés de la pyrazoline pour le traitement des troubles liées à la coagulation
EP1743889A1 (fr) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
EP1849784A1 (fr) *	2006-04-26	2007-10-31	Laboratorios Del Dr. Esteve, S.A.	Dérivés de la pyrazoline Indoline-substituée, leur préparation and utilisation comme médicaments
WO2007009706A2 (fr) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Composes de pyrazoline substitues, leur preparation et utilisation comme medicaments
ES2327203B1 (es) *	2005-07-15	2010-06-07	Laboratorios Del Dr. Esteve, S.A.	Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos relacionados con la coagulacion.
KR101457637B1 (ko) *	2012-10-24	2014-11-20	건국대학교 산학협력단	디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
CN103664785A (zh) *	2013-11-04	2014-03-26	南京大学	一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
US20230082841A1 (en) *	2021-09-14	2023-03-16	Maverick Gold (NV) LLC	Methods and systems for titling and trading alternative reserves

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ284157B6 (cs) *	1992-12-17	1998-08-12	Pfizer Inc.	Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
DE69422306T4 (de) *	1993-11-30	2000-09-07	G.D. Searle & Co., Chicago	Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5604253A (en) *	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5972986A (en) *	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2137138B1 (es) *	1998-05-29	2000-09-16	Esteve Labor Dr	Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
AU771668C (en) *	1999-06-16	2005-08-11	Temple University - Of The Commonwealth System Of Higher Education	1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2

2001
- 2001-04-06 ES ES200100818A patent/ES2174757B1/es not_active Expired - Fee Related
2002
- 2002-03-21 AT AT02714233T patent/ATE326966T1/de not_active IP Right Cessation
- 2002-03-21 AU AU2002246152A patent/AU2002246152B2/en not_active Ceased
- 2002-03-21 ES ES02714233T patent/ES2264723T3/es not_active Expired - Lifetime
- 2002-03-21 ZA ZA200308626A patent/ZA200308626B/en unknown
- 2002-03-21 HU HU0400918A patent/HUP0400918A3/hu unknown
- 2002-03-21 EP EP04030751A patent/EP1516621A3/fr not_active Withdrawn
- 2002-03-21 IL IL15826902A patent/IL158269A0/xx unknown
- 2002-03-21 PT PT02714233T patent/PT1384477E/pt unknown
- 2002-03-21 CN CNA2005100713090A patent/CN1698602A/zh active Pending
- 2002-03-21 CN CNB028098935A patent/CN1299682C/zh not_active Expired - Fee Related
- 2002-03-21 WO PCT/ES2002/000137 patent/WO2002080909A1/fr not_active Ceased
- 2002-03-21 CA CA2442974A patent/CA2442974C/fr not_active Expired - Fee Related
- 2002-03-21 JP JP2002578948A patent/JP4451599B2/ja not_active Expired - Fee Related
- 2002-03-21 NZ NZ529304A patent/NZ529304A/en unknown
- 2002-03-21 DE DE60211681T patent/DE60211681T2/de not_active Expired - Lifetime
- 2002-03-21 BR BR0208805-3A patent/BR0208805A/pt not_active IP Right Cessation
- 2002-03-21 KR KR10-2003-7013062A patent/KR20040025912A/ko not_active Ceased
- 2002-03-21 EP EP02714233A patent/EP1384477B1/fr not_active Expired - Lifetime
- 2002-03-21 UA UA2003119998A patent/UA75402C2/uk unknown
- 2002-03-21 DK DK02714233T patent/DK1384477T3/da active
- 2002-03-21 US US10/312,193 patent/US20040034082A1/en not_active Abandoned
- 2002-03-21 MX MXPA03009124A patent/MXPA03009124A/es active IP Right Grant
- 2002-03-21 PL PL02365220A patent/PL365220A1/xx not_active Application Discontinuation
- 2002-03-21 RU RU2003132457/15A patent/RU2305545C2/ru not_active IP Right Cessation
2003
- 2003-10-03 IS IS6973A patent/IS6973A/is unknown
- 2003-10-06 NO NO20034470A patent/NO20034470L/no not_active Application Discontinuation
- 2003-11-05 MA MA27382A patent/MA27019A1/fr unknown
2006
- 2006-08-03 CY CY20061101088T patent/CY1105523T1/el unknown

Also Published As

Publication number	Publication date
ES2174757B1 (es)	2003-11-01
ES2174757A1 (es)	2002-11-01
ZA200308626B (en)	2004-11-05
JP2004525166A (ja)	2004-08-19
EP1516621A3 (fr)	2005-05-04
PT1384477E (pt)	2006-09-29
EP1384477A1 (fr)	2004-01-28
IL158269A0 (en)	2004-05-12
HUP0400918A2 (hu)	2004-07-28
IS6973A (is)	2003-10-03
EP1384477B1 (fr)	2006-05-24
NO20034470D0 (no)	2003-10-06
HK1067311A1 (en)	2005-04-08
MXPA03009124A (es)	2005-04-11
US20040034082A1 (en)	2004-02-19
WO2002080909A1 (fr)	2002-10-17
DE60211681D1 (de)	2006-06-29
RU2003132457A (ru)	2005-04-10
CY1105523T1 (el)	2010-07-28
JP4451599B2 (ja)	2010-04-14
RU2305545C2 (ru)	2007-09-10
CA2442974A1 (fr)	2002-10-17
ATE326966T1 (de)	2006-06-15
ES2264723T3 (es)	2007-01-16
AU2002246152B2 (en)	2007-05-31
NO20034470L (no)	2003-12-05
CN1299682C (zh)	2007-02-14
NZ529304A (en)	2006-02-24
DK1384477T3 (da)	2006-08-21
CN1698602A (zh)	2005-11-23
HUP0400918A3 (en)	2004-10-28
CN1509171A (zh)	2004-06-30
KR20040025912A (ko)	2004-03-26
PL365220A1 (en)	2004-12-27
EP1516621A2 (fr)	2005-03-23
MA27019A1 (fr)	2004-12-20
BR0208805A (pt)	2004-07-13
CA2442974C (fr)	2010-02-23
DE60211681T2 (de)	2007-05-16

Publication	Publication Date	Title
UA75402C2 (en)	2006-04-17	Use of pyrazoline derivative for the preparation of medicament for prevention or treatment of proliferative cellular diseases
ES2381174T3 (es)	2012-05-23	Derivados de isoindolina farmacéuticamente activos
JP7295169B2 (ja)	2023-06-20	Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法
JP4342939B2 (ja)	2009-10-14	ピラゾール誘導キナーゼインヒビターおよびその使用
JP6781736B2 (ja)	2020-11-04	新規な４，６−二置換アミノピリミジン誘導体
JP6720225B2 (ja)	2020-07-08	ヘテロアリール置換のアミノピリジン化合物
RU2757218C2 (ru)	2021-10-12	Аминопиразолы в качестве селективных ингибиторов янус-киназы
HUP0302922A2 (hu)	2003-12-29	Sejtburjánzást gátló hatású imidazolo-5-il-2-anilino-pirimidinek és ezeket tartalmazó gyógyszerkészítmények
TW201402555A (zh)	2014-01-16	含氮雜環化合物或其鹽
PL185361B1 (pl)	2003-04-30	N-podstawione związki ftalimidowe jako inhibitory TNF
CN104262328A (zh)	2015-01-07	抑制btk和/或jak3激酶活性的化合物
SK86797A3 (en)	1998-01-14	Aryl amides as immunotherapeutically effective substances at reducing tnf- alpha level, pharmaceutical composition and use
AU2013277154A1 (en)	2014-12-18	Complement pathway modulators and uses thereof
WO2014080290A2 (fr)	2014-05-30	Amines cycliques servant d'inhibiteurs de bromodomaines
KR20030020925A (ko)	2003-03-10	피리미딘 유도체
CN110818641B (zh)	2022-10-14	哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN102471280B (zh)	2014-08-06	吡唑衍生物、其制备及其治疗用途
TWI640510B (zh)	2018-11-11	Ｃｘｃｒ７受體調節劑
CN106795146A (zh)	2017-05-31	作为突变型异柠檬酸脱氢酶1抑制剂的异噁唑衍生物
CN105579457A (zh)	2016-05-11	取代的n-联苯-3-乙酰基氨基-苯甲酰胺和n-[3-(乙酰基氨基)苯基]-联苯-甲酰胺及其作为wnt信号通路抑制剂用途
WO2016041472A1 (fr)	2016-03-24	Méthode de préparation d'un composé hétérocyclique aromatique utilisé comme inhibiteur sélectif de la kinase jak3 et/ou jak1, et application dudit composé
SK86997A3 (en)	1998-01-14	Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha
US8202899B2 (en)	2012-06-19	Pyrazole urea derivatives used as kinase inhibitors
WO2022032484A1 (fr)	2022-02-17	Composé de pyridazine-3-formamide, son procédé de préparation et son utilisation médicale
JP2024541474A (ja)	2024-11-08	Ｃｄｋ９阻害剤として有用なピラゾロトリアジン誘導体